Showing results (891-900 of 1,191) with videos related to
Sort By:
Pageof 120
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 9, 2021
Myelodysplastic syndrome with t(6;9)(p22;q34.1)/DEK-NUP214 better classified as acute myeloid leukemia? A multicenter study of 107 casesHong Fang, Mariko Yabe, Xiaohui Zhang, et al.American Journal of Hematology|April 26, 2021
Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemiaTapan M Kadia, Farhad Ravandi, Gautam Borthakur, et al.Cancer|March 19, 2016
Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignanciesGautam Borthakur, Leslie Popplewell, Michael Boyiadzis, et al.Kidney International Supplements|July 15, 2014
Latin American Dialysis and Transplant Registry: 2008 prevalence and incidence of end-stage renal disease and correlation with socioeconomic indexesAna M Cusumano, Guillermo Garcia-Garcia, Maria C Gonzalez-Bedat, et al.Cancer|August 27, 2015
Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemiaFarhad Ravandi, Susan M O'Brien, Jorge E Cortes, et al.American Journal of Hematology|January 4, 2022
Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classificationPatrick K Reville, Koji Sasaki, Hagop M Kantarjian, et al.American Journal of Hematology|October 30, 2022
A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromesAmer M Zeidan, Uma Borate, Daniel A Pollyea, et al.Nature Communications|March 19, 2024
Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with myelodysplastic syndromesJuan Jose Rodriguez-Sevilla, Irene Ganan-Gomez, Feiyang Ma, et al.Blood|July 7, 2026
Tagraxofusp, Azacitidine, and Venetoclax in Blastic Plasmacytoid Dendritic Cell NeoplasmAndrew A Lane, Marlise R Luskin, Julia H Keating, et al.Cancer|January 15, 2021
Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remissionIman Abou Dalle, Hagop M Kantarjian, Farhad Ravandi, et al.Pageof 120